| IJCEP Copyright © 2007-All rights reserved. |
Int J Clin Exp Pathol 2010;3(7):705-709
Original Article
Anti-angiogenic effects of epigallocatechin-3-gallate in human skin
Diana Santo Domingo, Melissa M. Camouse, Andrew H. Hsia, Mary Matsui, Daniel Maes, Nicole L. Ward, Kevin D. Cooper, Elma D. Baron
University Hospitals Case Medical Center, Departments of Dermatology; The Case Skin Diseases Research Center; The Case
Comprehensive Cancer Center, Cleveland, OH 44106; Louis-Stokes VA Medical Center, 10701 East Boulevard, Cleveland , OH 44106; Estee
Lauder Research Division, 125 Pinelawn Rd., Melville, NY 11747, USA.
Received July 10, 2010; accepted July 31, 2010; available online August 5, 2010
Abstract: Epigallocatechin-3-gallate (EGCG) is the main polyphenol component of green tea. This compound exhibits antioxidant,
immunomodulatory, photoprotective, anti-angiogenic, and anti-inflammatory properties. We conducted a small randomized, double blind, split
face trial using a cream containing 2.5% w/w of EGCG. Four healthy volunteers with significant erythema and telangiectasia on the face applied
EGCG cream to one side of the face, and vehicle control cream to the other, twice daily for six weeks. After six weeks, biopsies were taken from
EGCG and vehicle treated sites. Immunohistochemistry was used to measure VEGF and HIF-1α. HIF-1α expression was decreased in EGCG
treated sites, such that 28.4% of the epidermis showed positive staining in vehicle treated vs. 13.8% in EGCG treated sites (p<0.001). A similar
decrease in VEGF expression was found (6.7% in EGCG vs. 11.0%in in vehicle-treated skin (p<0.005). EGCG topical treatments influence HIF-
1α induction and VEGF expression and may serve as a potential agent in the prevention of telangiectasias. (IJCEP1007004).
Keywords: VEGF, Green tea, EGCG, skin, Rosacea, HIf-1α, angiogenesis
Full text PDF
Address all correspondence to:
Elma Baron, MD.
Department of Dermatology
School of Medicine
Case Western Reserve University
10900 Euclid Avenue
Cleveland, OH 44106-4942
Phone: (216) 368-4971, FAX: (216) 844-7815
Email: elma.baron@UHhospitals.org
Original Article
Anti-angiogenic effects of epigallocatechin-3-gallate in human skin
Diana Santo Domingo, Melissa M. Camouse, Andrew H. Hsia, Mary Matsui, Daniel Maes, Nicole L. Ward, Kevin D. Cooper, Elma D. Baron
University Hospitals Case Medical Center, Departments of Dermatology; The Case Skin Diseases Research Center; The Case
Comprehensive Cancer Center, Cleveland, OH 44106; Louis-Stokes VA Medical Center, 10701 East Boulevard, Cleveland , OH 44106; Estee
Lauder Research Division, 125 Pinelawn Rd., Melville, NY 11747, USA.
Received July 10, 2010; accepted July 31, 2010; available online August 5, 2010
Abstract: Epigallocatechin-3-gallate (EGCG) is the main polyphenol component of green tea. This compound exhibits antioxidant,
immunomodulatory, photoprotective, anti-angiogenic, and anti-inflammatory properties. We conducted a small randomized, double blind, split
face trial using a cream containing 2.5% w/w of EGCG. Four healthy volunteers with significant erythema and telangiectasia on the face applied
EGCG cream to one side of the face, and vehicle control cream to the other, twice daily for six weeks. After six weeks, biopsies were taken from
EGCG and vehicle treated sites. Immunohistochemistry was used to measure VEGF and HIF-1α. HIF-1α expression was decreased in EGCG
treated sites, such that 28.4% of the epidermis showed positive staining in vehicle treated vs. 13.8% in EGCG treated sites (p<0.001). A similar
decrease in VEGF expression was found (6.7% in EGCG vs. 11.0%in in vehicle-treated skin (p<0.005). EGCG topical treatments influence HIF-
1α induction and VEGF expression and may serve as a potential agent in the prevention of telangiectasias. (IJCEP1007004).
Keywords: VEGF, Green tea, EGCG, skin, Rosacea, HIf-1α, angiogenesis
Full text PDF
Address all correspondence to:
Elma Baron, MD.
Department of Dermatology
School of Medicine
Case Western Reserve University
10900 Euclid Avenue
Cleveland, OH 44106-4942
Phone: (216) 368-4971, FAX: (216) 844-7815
Email: elma.baron@UHhospitals.org
 | |  | |  | |  | |  | |  |
